Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle

Molecular Endocrinology

Volumn 20, Issue 12, 2006, Pages 3364-3375

  Al Khalili, Lubna ^a   Bouzakri, Karim ^a   Glund, Stephan ^a   Lönnqvist, Fredrik ^a,b   Koistinen, Heikki A ^c   Krook, Anna ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Biovitrum AB ^*  (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CCAAT ENHANCER BINDING PROTEIN ALPHA; FATTY ACID; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; GLYCOGEN SYNTHASE; INTERLEUKIN 6; LIPID; MESSENGER RNA; MYOCYTE ENHANCER FACTOR 2; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; UNCOUPLING PROTEIN 2;

ARTICLE; DRUG INHIBITION; FEMALE; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LIPID METABOLISM; LIPID OXIDATION; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELLS, CULTURED; CHROMONES; FATTY ACIDS; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 4; GLYCOGEN; HUMANS; INTERLEUKIN-6; LACTIC ACID; LIPID METABOLISM; MORPHOLINES; MULTIENZYME COMPLEXES; MUSCLE FIBERS; MUSCLE, SKELETAL; OXIDATION-REDUCTION; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 33751501694     PISSN: 08888809     EISSN: 08888809     Source Type: Journal    
DOI: 10.1210/me.2005-0490     Document Type: Article

References (71)

1. Foulstone EJ, Savage PB, Crown AL, Holly JM, Stewart CE 2003 Role of insulin-like growth factor binding protein-3 (IGFBP-3) in the differentiation of primary human adult skeletal myoblasts. J Cell Physiol 195:70-79
2. Bartoccioni E, Michaelis D, Hohlfeld R 1994 Constitutive and cytokine-induced production of interleukin-6 by human myoblasts. Immunol Lett 42:135-138
3. Kurek JB, Nouri S, Kannourakis G, Murphy M, Austin L 1996 Leukemia inhibitory factor and interleukin-6 are produced by diseased and regenerating skeletal muscle. Muscle Nerve 19:1291-1301
4. Tews DS, Goebel HH 1996 Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 55:342-347
5. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA 1996 The expression of TNF α by human muscle. Relationship to insulin resistance. J Clin Invest 97:1111-1116
6. Grobet L, Martin LJ, Poncelet D, Pirottin D, Brouwers B, Riquet J, Schoeberlein A, Dunner S, Menissier F, Massabanda J, Fries R, Hanset R, Georges M 1997 A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet 17:71-74
7. Nennesmo I, Olsson T, Ljungdahl A, Kristensson K, Van der Meide PH 1989 Interferon-γ-like immunoreactivity and T-cell marker expression in rat skeletal muscle fibres. Brain Res 504:306-310
8. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G 2001 Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745-E751
9. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW 1997 Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α in vivo. J Clin Endocrinol Metab 82:4196-4200
10. Steensberg A, Keller C, Starkie RL, Osada T, Febbraio MA, Pedersen BK 2002 IL-6 and TNF-α expression in, and release from, contracting human skeletal muscle. Am J Physiol Endocrinol Metab 283:E1272-E1278
11. Febbraio MA 2003 Signaling pathways for IL-6 within skeletal muscle. Exerc Immunol Rev 9:34-39
12. Febbraio MA, Pedersen BK 2002 Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J 16:1335-1347
13. Febbraio MA, Steensberg A, Starkie RL, McConell GK, Kingwell BA 2003 Skeletal muscle interleukin-6 and tumor necrosis factor-α release in healthy subjects and patients with type 2 diabetes at rest and during exercise. Metabolism 52:939-944
14. Keller P, Keller C, Carey AL, Jauffred S, Fischer CP, Steensberg A, Pedersen BK 2003 Interleukin-6 production by contracting human skeletal muscle: autocrine regulation by IL-6. Biochemical and Biophysical Research Communications 310:550-554
15. Keller SR 2003 The insulin-regulated aminopeptidase: a companion and regulator of GLUT4. Front Biosci 8:s410-s420
16. Baeza-Raja B, Munoz-Canoves P 2004 p38 MAPK-induced nuclear factor-κB activity is required for skeletal muscle differentiation: role of interleukin-6. Mol Biol Cell 15:2013-2026
17. Ravussin E, Smith SR 2002 Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann NY Acad Sci 967:363-378
18. Hill GE 1998 Cardiopulmonary bypass-induced inflammation: is it important? J Cardiothorac Vasc Anesth 12:21-25
19. Deng MC, Plenz G, Labarrere C, Marboe C, Baba HA, Erre M, Itescu S 2002 The role of IL6 cytokines in acute cardiac allograft rejection. Transpl Immunol 9:115-120
20. Conn CA, McClellan JL, Maassab HF, Smitka CW, Majde JA, Kluger MJ 1995 Cytokines and the acute phase response to influenza virus in mice. Am J Physiol 268:R78-R84
21. Kanda T, Takahashi T 2004 Interleukin-6 and cardiovascular diseases. Jpn Heart J 45:183-193
22. Cottam DR, Mattar SG, Barinas-Mitchell E, Eid G, Kuller L, Kelley DE, Schauer PR 2004 The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes Surg 14:589-600
23. Singh R, Robinson DB, El-Gabalawy HS 2005 Emerging biologic therapies in rheumatoid arthritis: cell targets and cytokines. Curr Opin Rheumatol 17:274-279
24. Sharma AM, Chetty VT 2005 Obesity, hypertension and insulin resistance. Acta Diabetologica 42:s3-s8
25. Klover PJ, Clementi AH, Mooney RA 2005 Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146:3417-3427
26. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE 2005 Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat Med 11:183-190
27. Senn JJ, Klover PJ, Nowak IA, Mooney RA 2002 Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391-3399
28. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA 2003 Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278:13740-13746
29. Rotter V, Nagaev I, Smith U 2003 Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-α, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278:45777-45784
30. Petersen EW, Carey AL, Sacchetti M, Steinberg GR, Macaulay SL, Febbraio MA, Pedersen BK 2005 Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am J Physiol Endocrinol Metab 288:E155-E162
31. Steensberg A, Fischer CP, Keller C, Moller K, Pedersen BK 2003 IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab 285:E433-E437
32. Kim H-J, Higashimori T, Park S-Y, Choi H, Dong J, Kim Y-J, Noh H-L, Cho Y-R, Cline G, Kim Y-B, Kim JK 2004 Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060-1067
33. Rotter Sopasakis V, Larsson BM, Johansson A, Holmang A, Smith U 2004 Short-term infusion of interleukin-6 does not induce insulin resistance in vivo or impair insulin signalling in rats. Diabetologia 47:1879-1887
34. Matthys P, Mitera T, Heremans H, Van Damme J, Billiau A 1995 Anti-γ interferon and anti-interleukin-6 antibodies affect staphylococcal enterotoxin B-induced weight loss, hypoglycemia, and cytokine release in D-galactosamine-sensitized and unsensitized mice. Infect Immun 63:1158-1164
35. Petersen AMW, Pedersen BK 2005 The anti-inflammatory effect of exercise. J Appl Physiol 98:1154-1162
36. van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, Hiscock N, Moller K, Saltin B, Febbraio MA, Pedersen BK 2003 Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 88:3005-3010
37. Kelly M, Keller C, Avilucea PR, Keller P, Luo Z, Xiang X, Giralt M, Hidalgo J, Saha AK, Pedersen BK, Ruderman NB 2004 AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Commun 320:449-454
38. Winder WW 2001 Energy-sensing and signaling by AMP-activated protein kinase in skeletal muscle. J Appl Physiol 91:1017-1028
39. Ruderman NB, Cacicedo JM, Itani S, Yagihashi N, Saha AK, Ye JM, Chen K, Zou M, Carling D, Boden G, Cohen RA, Keaney J, Kraegen EW, Ido Y 2003 Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes. Biochem Soc Trans 31:202-206
40. Winder WW, Hardie DG 1999 AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 277:E1-E10
41. Barnes BR, Ryder JW, Steiler TL, Fryer LGD, Carling D, Zierath JR 2002 Isoform-specific regulation of 5′ AMP-activated protein kinase in skeletal muscle from obese Zucker (fa/fa) rats in response to contraction. Diabetes 51:2703-2708
42. Kemp BE, Mitchelhill KI, Stapleton D, Michell BJ, Chen ZP, Witters LA 1999 Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem Sci 24:22-25
43. Jessen N, Pold R, Buhl ES, Jensen LS, Schmitz O, Lund S 2003 Effects of AICAR and exercise on insulin-stimulated glucose uptake, signaling, and GLUT-4 content in rat muscles. J Appl Physiol 94:1373-1379
44. Kurth-Kraczek EJ, Hirshman MF, Goodyear LJ, Winder WW 1999 5′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes 48:1667-1671
45. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S, Moller DE, Thorell A, Goodyear LJ 2002 Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51:2074-2081
46. Lazar C, Grigorescu-Sido P, Manasia R, Mirestean S, Skorka C, Neculoiu D, Molnar G, Cocean S 2005 Evaluation of viral replication in children with chronic hepatitis B with and without interferon treatment. Rom J Gastroenterol 14:219-224
47. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA 1990 Correlations and interactions in the production of interleukin-6 (IL- 6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 75:40-47
48. Tilg H, Dinarello CA, Mier JW 1997 IL-6 and APPs: antiinflammatory and immunosuppressive mediators. Immunol Today 18:428-432
49. Carey AL, Febbraio MA 2004 Interleukin-6 and insulin sensitivity: friend or foe? Diabetologia 47:1135-1142
50. Hiscock N, Chan MH, Bisucci T, Darby IA, Febbraio MA 2004 Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity. FASEB J 18:992-994
51. Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T, Kishimoto T 1989 Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573-581
52. Mullberg J, Schooltink H, Stoyan T, Heinrich PC, Rose-John S 1992 Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor. Biochem Biophys Res Commun 189:794-800
53. Schuster B, Meinert W, Rose-John S, Kallen KJ 2003 The human interleukin-6 (IL-6) receptor exists as a preformed dimer in the plasma membrane. FEBS Lett 538:113-116
54. Higashi N, Kunimoto H, Kaneko S, Sasaki T, Ishii M, Kojima H, Nakajima K 2004 Cytoplasmic c-Fos induced by the YXXQ-derived STAT3 signal requires the co-operative MEK/ERK signal for its nuclear translocation. Genes Cells 9:233-242
55. Jee S-H, Chu C-Y, Chiu H-C, Huang Y-L, Tsai W-L, Liao Y-H, Kuo M-L 2004 Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways. J Invest Dermatol 123:1169-1175
56. Weigert C, Hennige AM, Lehmann R, Brodbeck K, Baumgartner F, Schauble M, Haring HU, Schleicher ED 2006 Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. J Biol Chem 281:7060-7067
57. Bruce CR, Dyck DJ 2004 Cytokine regulation of skeletal muscle fatty acid metabolism: effect of interleukin-6 and tumor necrosis factor-α. Am J Physiol Endocrinol Metab 287:E616-E621
58. Aschenbach WG, Sakamoto K, Goodyear LJ 2004 5′ adenosine monophosphate-activated protein kinase, metabolism and exercise. Sports Med 34:91-103
59. Barnes BR, Marklund S, Steiler TL, Walter M, Hjalm G, Amarger V, Mahlapuu M, Leng Y, Johansson C, Galuska D, Lindgren K, Abrink M, Stapleton D, Zierath JR, Andersson L 2004 The 5′-AMP-activated protein kinase γ3 isoform has a key role in carbohydrate and lipid metabolism in glycolytic skeletal muscle. J Biol Chem 279:38441-38447
60. Sopasakis VR, Sandqvist M, Gustafson B, Hammarstedt A, Schmelz M, Yang X, Jansson PA, Smith U 2004 High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator. Obes Res 12:454-460
61. Okazaki S, Kawai H, Arii Y, Yamaguchi H, Saito S 1996 Effects of calcitonin gene-related peptide and interleukin 6 on myoblast differentiation. Cell Prolif 29:173-182
62. Al-Khalili L, Forsgren M, Kannisto K, Zierath JR, Lonnqvist F, Krook A 2005 Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor γ co-activator 1. Diabetologia 48:1173-1179
63. Silva JL, Giannocco G, Furuya DT, Lima GA, Moraes PA, Nachef S, Bordin S, Britto LR, Nunes MT, Machado UF 2005 NF-κB, MEF2A, MEF2D and HIF1-a involvement on insulin- and contraction-induced regulation of GLUT4 gene expression in soleus muscle. Mol Cell Endocrinol 240:82-93
64. Pilegaard H, Osada T, Andersen LT, Helge JW, Saltin B, Neufer PD 2005 Substrate availability and transcriptional regulation of metabolic genes in human skeletal muscle during recovery from exercise. Metabolism 54:1048-1055
65. Watt MJ, Southgate RJ, Holmes AG, Febbraio MA 2004 Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) α and δ and PPAR coactivator 1α in human skeletal muscle, but not lipid regulatory genes. J Mol Endocrinol 33:533-544
66. Blom PC, Costill DL, Vollestad NK 1987 Exhaustive running: inappropriate as a stimulus of muscle glycogen super-compensation. Med Sci Sports Exerc 19:398-403
67. Constantin-Teodosiu D, Casey A, Short AH, Hultman E, Greenhaff PL 1996 The effect of repeated muscle biopsy sampling on ATP and glycogen resynthesis following exercise in man. Eur J Appl Physiol Occup Physiol 73:186-190
68. Al-Khalili L, Chibalin AV, Kannisto K, Zhang BB, Permert J, Holman GD, Ehrenborg E, Ding VD, Zierath JR, Krook A 2003 Insulin action in cultured human skeletal muscle cells during differentiation: assessment of cell surface GLUT4 and GLUT1 content. Cell Mol Life Sci 60:991-998
69. Krook A, Moller DE, Dib K, O'Rahilly S 1996 Two naturally occurring mutant insulin receptors phosphorylate insulin receptor substrate-1 (IRS-1) but fail to mediate the biological effects of insulin. J Biol Chem 271:7134-7140
70. Somwar R, Sweeney G, Ramlal T, Klip A 1998 Stimulation of glucose and amino acid transport and activation of the insulin signaling pathways by insulin lispro in L6 skeletal muscle cells. Clin Ther 20:125-140
71. Al-Khalili L, Cartee GD, Krook A 2003 RNA interference-mediated reduction in GLUT1 inhibits serum-induced glucose transport in primary human skeletal muscle cells. Biochem Biophys Res Commun 307:127-132